🇺🇸#CLVS
Clovis Oncology: Early Clinical Experience From Named-Patient Use Validates Plans to Further Investigate FAP-2286 as a Therapeutic and Imaging Agent Across Variety of Solid Tumor Types
Clovis Oncology: Early Clinical Experience From Named-Patient Use Validates Plans to Further Investigate FAP-2286 as a Therapeutic and Imaging Agent Across Variety of Solid Tumor Types